Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse.
Click here for original story, New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma
Source: ScienceDaily